Fintel reports that on March 13, 2025, Citigroup initiated coverage of Apogee Therapeutics (NasdaqGM:APGE) with a Buy ...

Citi initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $95 price target Healthcare policy remains a key biopharma sector ...

Arizona State Retirement System grew its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 17.3% in the 4th quarter, according to its most recent Form 13F filing with the ...

Guggenheim analyst Seamus Fernandez raised the firm’s price target on Apogee Therapeutics (APGE) to $116 from $110 and keeps a Buy rating on ...

NASDAQ:APGE opened at $38.33 on Thursday. Apogee Therapeutics has a twelve month low of $29.10 and a twelve month high of $71.75. The business has a 50 day moving average price of $38.55 and a two ...

Shareware allowed budding developers to distribute their games affordably and reach a wider audience through copying and ...

On Monday (Feb. 17), the moon reaches what's known as apogee — its farthest point away from Earth. The moon's orbit is elliptical, or oval-shaped, meaning its distance from Earth changes ...

On Monday, Apogee Therapeutics, Inc. (NASDAQ:APGE) released interim Phase 1 results from its first-in-human trial of APG990. APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Apogee Therapeutics advanced after sharing positive interim results that push forward more trials of inflammatory and immunology treatments. The stock rose 6% to $33.37 on Monday. Shares ...

Apogee Entertainment and Emberheart Games released a new updated demo for Vexlands, giving Steam players an upgraded ...